Ozempic Gastroparesis Settlement: Washington Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Medication Safety Awareness

For decades, general health and science communication has served as a cornerstone of public understanding, bridging complex biomedical concepts with everyday wellness. This legacy emphasized broad awareness of medication benefits, disease prevention, and the importance of informed patient-provider dialogue. Within this framework, discussions around pharmaceutical interventions naturally evolved to include not only therapeutic efficacy but also the spectrum of potential adverse effects that may emerge during widespread clinical use. As the landscape of chronic disease management expanded, so too did the scrutiny of long-term medication safety profiles. A notable shift occurred when certain widely prescribed drugs, originally developed for metabolic conditions, began to be associated with gastrointestinal complications in a subset of patients. This observation prompted a more focused inquiry into the relationship between drug exposure and specific digestive system disturbances, moving the conversation from general health education into a specialized area of clinical and legal concern.

The Shift to Individual Harm: Ozempic and Gastroparesis in Washington

The pivot from general health context to individual harm arises when medication-related complications necessitate legal recourse. For individuals who have used medications such as Ozempic and subsequently developed gastroparesis, the question of liability and compensation becomes paramount. This transition reframes the discussion from population-level health information to the individual’s experience of harm, particularly in jurisdictions like Washington where legal pathways for injury claims are established. The focus now shifts to the practical implications of drug exposure and the pursuit of settlement for those affected.

Clinical Evidence: Ozempic and Gastrointestinal Adverse Reactions

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is prescribed for glycemic control in type 2 diabetes. However, its use has been associated with significant gastrointestinal adverse effects, including gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the delayed gastric emptying induced by GLP-1 agonists is a recognized mechanism that can precipitate or exacerbate the condition.

Mechanistic Pathways and Risk Considerations

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's effect on gastric motility. GLP-1 receptors are expressed in the gastrointestinal tract, and their activation slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This effect is dose-dependent and can become pathological in susceptible individuals, leading to symptomatic gastroparesis. The timeline between exposure and documented harm varies; symptoms often emerge during dose escalation, as noted in clinical trials, but may also develop after prolonged use. The label does not provide specific data on gastroparesis incidence, but the high rate of gastrointestinal adverse reactions suggests a significant risk. Risk considerations for affected patients include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically mention gastroparesis. Serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported, and caution is advised in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of this potential complication. This gap in labeling could be relevant in settlement-related considerations for affected patients, as it raises questions about whether the manufacturer adequately communicated the risk.

Settlement Considerations for Washington Patients

Settlement-related considerations for patients who develop gastroparesis after using Ozempic include the need to establish a causal link between the drug and the condition. This requires documentation of the timeline between exposure and symptom onset, as well as exclusion of other causes. The clinical trial data show that gastrointestinal adverse reactions are common and dose-related, supporting a plausible association. Patients may seek compensation for medical expenses, lost wages, and pain and suffering. Legal claims often hinge on whether the manufacturer provided sufficient warnings about the risk of gastroparesis. Given that the label does not explicitly mention this condition, plaintiffs may argue that the warnings were inadequate. In summary, Ozempic use is associated with a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug's mechanism of delaying gastric emptying provides a plausible pathway for this harm. The adequacy of warnings regarding gastroparesis is a key risk consideration, and affected patients may have settlement-related claims. Healthcare providers should monitor patients for signs of gastroparesis, especially during dose escalation, and consider alternative treatments if symptoms develop.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can lead to or exacerbate gastroparesis, a condition of delayed gastric emptying without obstruction. Clinical trials show high rates of gastrointestinal adverse reactions, including nausea, vomiting, and dyspepsia, which are consistent with gastroparesis symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Can I file a lawsuit in Washington if I developed gastroparesis from Ozempic?

Yes, Washington residents who developed gastroparesis after using Ozempic may have legal grounds for a claim if they can establish a causal link and show that the manufacturer failed to provide adequate warnings about the risk. Legal consultation is recommended to evaluate individual circumstances.

What evidence is needed for an Ozempic gastroparesis settlement?

Key evidence includes medical records documenting gastroparesis diagnosis (e.g., gastric emptying scintigraphy), prescription records showing Ozempic use, and a timeline linking exposure to symptom onset. Exclusion of other causes is also important. Clinical trial data supporting the association can strengthen the claim.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.